CompletedPhase 3

A Study of GC1111 in Hunter Syndrom Patients

South Korea32 participantsStarted 2017-03-09

Plain-language summary

The objective of this study is to evaluate the efficacy of GC1111 in Hunter Syndrome Patients

Who can participate

Age range

5 Years

Sex

MALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients diagnosed with Hunter syndrome * Male at the age of ≥ 5 * Adequate abilities (including 6-MWT) to participate in this study in the opinion of the investigator. * Voluntarily signed written informed consent to participation in this study * Consent to contraception Exclusion Criteria: * Prior treatment with iduronate-2-sulfatase ERT * History of bronchotomy, bone marrow trasplanation, or cord blood transplanation. * Known hypersensitivity reactions to any of the components of the invetigational product * Prior or planned administration of other investigational products within 30 days before treatment with the investigational product in this study or duirng this study. * Unable to perform 6-MWT. * Female

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change in 6-MWT

Timeframe: at Week 53 from baseline

Trial details

NCT IDNCT03920540

SponsorGreen Cross Corporation

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-02-15

View on ClinicalTrials.gov More Hunter Syndrome trials